Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Zaja

Showing results (91-100 of 145) with videos related to

Pageof 15
Sort By:
Blood|July 12, 2019
Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemiaPhilipp B Staber, Marco Herling, Mar Bellido, et al.
Blood|August 12, 2009
Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behaviorFrancesco Forconi, Elisa Sozzi, Emanuele Cencini, et al.
Journal of Hematology & Oncology|November 29, 2013
Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical applicationFederico Pozzo, Michele Dal Bo, Nadia Peragine, et al.
The Oncologist|March 22, 2006
Nongastric marginal-zone B-cell MALT lymphoma: prognostic value of disease disseminationLuca Arcaini, Sara Burcheri, Andrea Rossi, et al.
Expert Opinion on Biological Therapy|May 17, 2017
New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment?Francesca Patriarca, Luisa Giaccone, Francesco Onida, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 26, 2004
Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphomaPier Luigi Zinzani, Alessandro Pulsoni, Alessio Perrotti, et al.
Hematological Oncology|May 20, 2017
Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana LinfomiStefano Luminari, Elda Viel, Andrés José Maria Ferreri, et al.
Leukemia & Lymphoma|August 20, 2011
Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 10th annual conference of the European Mantle Cell Lymphoma NetworkMartin Dreyling, Hanneke C Kluin-Nelemans, Sílvia Beà, et al.
Blood|January 9, 2019
Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCLMagdalena Klanova, Laurie H Sehn, Isabelle Bence-Bruckler, et al.
The New England Journal of Medicine|May 12, 2021
Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell LeukemiaEnrico Tiacci, Luca De Carolis, Edoardo Simonetti, et al.
Pageof 15

Showing results (91-100 of 145) with videos related to

Sort By:
Pageof 15
Blood|July 12, 2019
Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemiaPhilipp B Staber, Marco Herling, Mar Bellido, et al.
Blood|August 12, 2009
Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behaviorFrancesco Forconi, Elisa Sozzi, Emanuele Cencini, et al.
Journal of Hematology & Oncology|November 29, 2013
Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical applicationFederico Pozzo, Michele Dal Bo, Nadia Peragine, et al.
The Oncologist|March 22, 2006
Nongastric marginal-zone B-cell MALT lymphoma: prognostic value of disease disseminationLuca Arcaini, Sara Burcheri, Andrea Rossi, et al.
Expert Opinion on Biological Therapy|May 17, 2017
New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment?Francesca Patriarca, Luisa Giaccone, Francesco Onida, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 26, 2004
Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphomaPier Luigi Zinzani, Alessandro Pulsoni, Alessio Perrotti, et al.
Hematological Oncology|May 20, 2017
Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana LinfomiStefano Luminari, Elda Viel, Andrés José Maria Ferreri, et al.
Leukemia & Lymphoma|August 20, 2011
Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 10th annual conference of the European Mantle Cell Lymphoma NetworkMartin Dreyling, Hanneke C Kluin-Nelemans, Sílvia Beà, et al.
Blood|January 9, 2019
Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCLMagdalena Klanova, Laurie H Sehn, Isabelle Bence-Bruckler, et al.
The New England Journal of Medicine|May 12, 2021
Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell LeukemiaEnrico Tiacci, Luca De Carolis, Edoardo Simonetti, et al.
Pageof 15